Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Enters PGx Pact with German Heart Hospital

NEW YORK (GenomeWeb News) – Clinical Data today said that it has entered into a research collaboration with Deutsches Herzzentrum (DHZ), a Munich, Germany-based heart hospital, to evaluate the predictive value of genetic markers for response to clopidogrel (Plavix).

The Newton, Mass.-based firm said that researchers from its PGx Health division will work with scientists from DHZ, which is affiliated with the Technical University of Munich, to conduct a large retrospective case/control study to validate genetic variants associated with response to the antiplatelet agent, which is marketed by Bristol-Myers Squibb and Sanofi Aventis.

Clinical Data said that several known genetic variants and its own proprietary markers will be evaluated during the study. The partners also will seek to identify new genetic predictors of clopidogrel response. They expect to obtain preliminary data from the studies in 2010.

"While the role of CYP2C19 in poor response to clopidogrel is widely known, it is clear that this gene does not account for all the variability in response," Marcia Lewis, VP of biomarker development at PGxHealth, said in a statement. "[T]his collaboration will expand our knowledge, as well as support development of a test that is highly predictive of individual response to clopidogrel."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.